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Abstract
Production of structural proteins from foot-and-mouth disease virus (FMDV) and bovine herpes virus (BHV-1) in Nicotiana benthamiana
through the use of a tobacco mosaic virus-based vector (TMV-30B) has been reported previously. The development of the TMV-30B-HISc
vector, a new version that adds a C-terminal histidine (His) sequence to the foreign protein expressed is described. Coding sequences from
the FMDV VPl protein and the core protein, p24, from a clade C HIV-1 isolate from Zambia were cloned into the new vector and infective
RNAs were generated for each construct to inoculate N. benthamiana plants. His-tagged proteins were purified from inoculated leaves using
immobilized metal affinity chromatography (IMAC) as detected by Coomassie blue staining and proteins were further characterized in Western
blot assays using a commercial anti-6xHis mAb and specific polyclonal antisera for each protein. While yields obtained for the VPl-His protein
after purification were similar to those in crude extracts obtained with the previous TMV-VPl vector, p24-His yields were 10–15 times higher
than those of VPl-His. Twenty-five grams of TMV-p24-HISc inoculated leaves were processed to obtain 2.5 mg of isolated p24-His and
the recombinant protein was inoculated in rabbits to test immunogenicity and antigenic integrity of the plant-produced p24-His. Animals
developed a strong and specific humoral response to the p24-His after the first booster and immune sera was able to recognize the native
p24 from a different clade expressed on the surface of the HIV-1 chronically infected HUT78/ARV T-cell line. Importantly, the recombinant
p24-His proved its efficiency by confirming the serology of 117 samples previously tested by two rapid HIV-1 tests, thus representing an
excellent alternative for production of highly specific diagnostic reagents for HIV endemic regions in the developing world.
© 2004 Elsevier B.V. All rights reserved.
Keywords: HIV; Plant expression; Diagnosis; TMV-vector; Immune response

1. Introduction
Plants represent one of the main sources of biomass for
economical production of recombinant biological products,
especially when compared with traditional fermentation or
cell culture based methods (Giddings et al., 2000; Kusnadi
et al., 1997; Walmsley and Arntzen, 2003). In the recom∗ Corresponding author. Present address: Depto. Biotecnologı́a, INIAMadrid, Ctra. A Coruña Km.7, Madrid 28040, Spain. Tel.: +34 91 347 3794;
fax: +34 91 357 3157.
E-mail address: mperez@inia.es (D.M. Pérez-Filgueira).

0166-0934/$ – see front matter © 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.jviromet.2004.06.022

binant vaccine field, development of transgenic plants for
the gene of interest has represented the classical approach
over the past 12 years (Mason et al., 1992; Walmsley and
Arntzen, 2000). However, foreign proteins can also be obtained in plants by transient expression using plant virusbased vectors, an alternative which presents advantages over
constitutive expression from a transgenic plant (Lacomme
et al., 1998). Vectors have been developed utilizing several different groups of plant viruses, with positive single
stranded RNA (ssRNA) viral vectors being the most common (Pogue, 2002; Johnson et al., 1997). Some advantages of
small ssRNA viruses include small genomes that can be easily
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manipulated from cDNA clones and the potential to generate
high yields of viral protein, up to 10% of the dry weight of
the plant (Siegel et al., 1978). They can be applied to mature
plants, avoiding toxicity and potential developmental problems associated with constitutive expression of the foreign
protein. In addition, the products can be targeted to different
locations to facilitate recovery of the recombinant proteins
(McCormick et al., 1999). Those derived from members of
the Tobamovirus group (tobacco mosaic virus, TMV) are
among the most successful applications of this technology
(Yusibov et al., 1999). TMV-based vectors, first developed
15 years ago, have since been modified to improve stability
and permit enhanced expression of foreign genes (Toth et
al., 2002). We have previously utilized the TMV-30B vector
(Shivprasad et al., 1999) to express proteins of antigenic relevance for possible use as vaccines against foot and mouth
disease virus (FMDV) (Wigdorovitz et al., 1999) and bovine
herpesvirus-1 (BHV-1) (Pérez-Filgueira et al., 2003). However, similar studies conducted for other foreign proteins,
presented problems with reliable quantification and specific
immuno-detection of the recombinant products in the plant
extracts, due to background problems resulting from crossreactivity of the viral antiserum with plant proteins. Here we
describe a simple modification we made to the TMV-30B
vector to overcome these problems and its practical application in a very relevant model as human immunodeficiency
virus type 1 (HIV-1).
The new vector, designated TMV-30B-HISc, was constructed so that seven histidine (7xHis) residues would be
appended to the C-terminus of the foreign insert. Addition
of this 7xHis tag would not only permit a one-step purification of the foreign protein by immobilized metal affinity
chromatography (IMAC) (Nilsson et al., 1997), but it would
also facilitate quantification and a more reliable detection
of recombinant proteins in Western blot assays using a
commercially available monoclonal antibody against the His
sequence. To test the system, the VP1 open reading frame
(ORF) from the FMDV O1 Campos strain was introduced
into the modified vector to directly compare the production
and recovery of the recombinant VPl-His protein with the
VP1 produced with the original TMV-30B vector previously
reported (Wigdorovitz et al., 1999).
The new His-tagged vector was also tested for economical production of the p24 ORF from HIV-1, as this protein
was stably expressed in plants previously (Zhang et al., 2000,
2002) and based on our specific need to generate large quantities of the protein for routine diagnostic testing of clade
C HIV-1 in sub-Saharan Africa. The p24 capsid protein of
HIV-1 is a major component of the gag polyprotein and is
an important early marker of HIV-1 infection. Consequently,
this protein is routinely included in commercial assays for
diagnosing HIV-1 infection. In addition, the World Heath
Organization and Centers for Disease Control recommend
that Western blot confirmatory tests for HIV-1 infection must
detect antibodies to p24 capsid protein among other viral proteins. Epitope mapping studies with HIV-1 have shown that

p24 contains several cytotoxic T lymphocyte (CTL) epitopes
that are important for immune control of HIV-1 infection
(Johnson et al., 1991; Novitsky et al., 2002) and strong CTL
responses have been shown to be necessary for successful
vaccination in primates (Amara et al., 2001; Barouch et al.,
2001; Shiver et al., 2002). Taken together, it is evident that
p24 is an important antigen for controlling HIV-1 infection,
it can be used in reliably and accurately diagnosing HIV infection, and more importantly, it can be included potentially
in a preventive vaccine (Lefrere et al., 1992; Benson et al.,
1999).
The results presented below show that the TMV30B-HISc
vector represents a very useful tool for transient expression
of foreign antigens in plants, allowing facile detection, purification and quantification of recombinant products. Antigenic
features of the original p24 were preserved in the recombinant version. The plant-produced p24-His was able to induce
antibodies in rabbits that recognized the native p24 in cell
cultures and Western blot assays based on the recombinant
p24-His presented, for all the samples, concordant results
with two other commercial assays. Our results also suggest
that this approach offers a very inexpensive means for producing antigens and diagnostic reagents in plants. Estimations based on this confirmatory Western blot test and on the
yields of purified p24-His shown here indicate that the recombinant p24-His obtained from 25 g of fresh leaves would
be sufficient to conduct over 20,000 individual assays.

2. Materials and methods
2.1. Plasmid constructions
To introduce the 7xHis tag into the TMV-30B vector, a
fragment containing the ORF from the FMDV/O1 Campos
VP1 was amplified by PCR from the TMV-VP1 plasmid
(Wigdorovitz et al., 1999). The direct primer was used to
introduce a Pac I site upstream of the VP1 start codon and
the reverse primer was designed to introduce, from 3 to 5 ,
the Xho I and Pme I sites, and the 7xHis in frame with the 3
end of the VP1 ORF. The 704 bp PCR fragment was cloned
into the TMV-30B vector (Shivprasad et al., 1999) using the
Pac I and Xho I sites of the vector polylinker. The resulting
TMV-VPlHISc plasmid was digested with Pac I and Pme I
enzymes to liberate the VP1 ORF and produce an open plasmid containing the TMV-30BHISc vector. The p24 sequence
was amplified from genomic DNA isolated from peripheral
blood mononuclear cells (PBMC) of an HIV-1 infected Zambian patient through two rounds of PCR using nested primers.
The final 715 bp PCR product contained the Pac I and Pme
I sites at the 5 and 3 ends, respectively. These restriction
sites were utilized to clone the p24 fragment into the open
TMV-30BHISc vector to produce the TMV-p24-HISc plasmid (Fig. 1). Constructs were sequenced to confirm correct
insertion of the foreign ORFs and integrity of the reading
frames.
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Fig. 1. Schematic diagram of the TMV-30B-HISc vector. VP1 and p24 ORFs were amplified by PCR carrying the Pac I and Pme I restriction sites and cloned
in frame with 7xHis [(CAT)7 ] and the stop codon of the vector. Small arrows indicate subgenomic promoters for the movement protein (mp), coat protein (cp)
and foreign ORF (white arrow). Viral RNA transcripts were obtained after plasmid linearization at the Kpn I site and in vitro transcription was driven from the
T7 promoter located upstream of the 5 end of the vector’s replicase gene.

2.2. Plant inoculation
The TMV-VPlHISc and TMV-p24-HISc plasmids were
digested with Kpn I to generate linear templates for in vitro
production of run-off capped transcripts (Amplicap T7 transcription Kit, Epicentre Technology). Viral RNA was quantified by electrophoresis and approximately 2 g of viral RNA
per plant was applied to the upper surface of Nicotiana benthamiana leaves, as previously described (Pérez-Filgueira et
al., 2003). Plants were kept in growth chambers (16 h/day
of light, 29 ◦ C day temperature, 24 ◦ C night temperature)
and leaves were harvested 7 days post-inoculation (dpi) and
frozen at −20 ◦ C until processed.
2.3. Production and puriﬁcation of recombinant proteins
Inoculated plant leaves were ground in extraction buffer
containing phosphate saline (PBS)/8 M urea (pH 8.0). Clarified sap was obtained after passing the ground suspension
through a Miracloth filter (Calbiochem) and centrifugation
at 15,000 × g for 10 min. IMAC beads (Talon, Clontech)
were resuspended in the same extraction buffer and incubated with the clarified sap for l h at room temperature (RT).
Beads were then washed three times in PBS/8 M urea (pH
6.3), placed in columns and His-tagged proteins were eluted
with 6 M urea/300 mM NaCl/50 mM Na acetate using a pH
gradient from 5.8 to 4.8.
2.4. Protein analysis
IMAC elution fractions and bead samples were resolved
in duplicate 12% SDS-PAGE gels for Coomassie blue staining and transfer onto ECL nitrocellulose membranes (Amersham). For Western blot analysis, membranes were blocked
overnight with PBS-tween 20 (PBST) containing 4% skim
milk, and subsequently incubated at room temperature (RT)
with a primary antibody-specific for the recombinant pro-

tein and a species-specific HRP-labelled conjugate as secondary antibody. Protein bands were detected using the ECL
Western blotting detection system (Amersham) on X-ray film
(Kodak). His-tag detection was carried out using an anti6xHis mAb (Clontech) and anti-IgG mouse HRP-labelled
conjugate as secondary antibody. Polyclonal mouse serum
against the 135–160 amino acid sequence (p135–160) of VPl
FMDV OIC (Zamorano et al., 1994) was used as the primary antibody for VPl detection. A pool of sera from HIV1 positive patients was used as the primary antibody for
p24 detection with anti-human Ig HRP-labelled conjugate
as a secondary antibody. For re-probing assays, membranes
were incubated with a stripping buffer containing Tris–HCl,
62.5 mM/2-mercaptoethanol, 100 mM/SDS, 2% for 30 min at
50 ◦ C and washed with PBS before performing Western blot
analysis as described above. The concentration of each recombinant protein was estimated from known bovine serum
albumin standards by Coomassie blue staining in conjunction
with the BioRad Fluor S Multilmager System and Quantity
One 4.0 software (BioRad).
2.5. Animal immunizations
Two female rabbits were immunized with the purified
recombinant p24-His diluted in elution buffer. The immunogens for the first inoculation were formulated containing complete Freund adjuvant and 0.5 mg of recombinant
protein/dose. A second immunization was performed with
0.25 mg of recombinant protein/dose and incomplete Freund adjuvant 15 days post-initial immunization. Rabbits were
bled at 30, 45 and 60 days after the first inoculation.
2.6. Immunoﬂuorescence assay (IFA)
HUT 78/ARV cells, a human T lymphoma cell line chronically infected with HIV-1, were utilized for detection of antibodies to p24 as previously described (Mantina et al., 2001).
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Briefly, HUT78/ARV cells were spotted onto slides at a concentration of 5 × 105 cells/ml, air dried and fixed in cold acetone. Slides were sequentially incubated at 37 ◦ C for 30 min
with rabbit anti-p24 sera, DTAF-conjugated anti-rabbit antibody; and slides were washed with PBS in between incubations. Slides were then incubated with Evans blue (0.004%)
for 3 min to counter stain cells.
2.7. Rapid qualitative testing and Western blot for HIV-1
Rapid qualitative testing for HIV was performed with the
DetermineTM and CapillusTM assays according to the manufacturer and as previously described (Abbott Laboratories,
Abbott Park, IL; Trinity Biotech, Bray, Co Wicklow, Ireland). Positive test strips were visually determined for each
case. Samples with concordant positive results for both rapid
tests were considered positive and a subset was subjected
to confirmation by Western blot against the HIV-1 recombinant p24-His. Purified plant-produced p24-His was added
to preparative gels estimating 0.1 g of recombinant protein
per sample lane, resolved by SDS PAGE and Western blotted
as described above. Blots were divided in strips and sequentially incubated with the human serum and an anti-human
IgG alkaline-phosphatase conjugate, each for 1 h at 37 ◦ C.
Strips were finally developed with NBT/BCIP substrate and
visually analyzed as mentioned for commercial rapid HIV
tests.

3. Results
3.1. Expression of FMDV VP1 using the TMV30B-HISc
vector
Results were described on the production of recombinant
VP1 protein (Wigdorovitz et al., 1999) using the TMV-30B
vector (Shivprasad et al., 1999). These experiments were repeated here to allow for a direct comparison of the production
of VP1 cloned into the TMV-30B-HISc vector. Equivalent
amounts of RNA transcript from TMV-30B, TMV-VP1 and
TMV-VP1-HISc constructs were inoculated on plant leaves

that were harvested at 7 dpi. Protein samples obtained from
25 mg of fresh tissue were compared by SDS PAGE (Fig. 2A)
and analyzed by Coomassie blue staining. The TMV coat protein band of 18 kDa is evident in TMV-30B infected sample
(lane 3) as expected. A band of expected size for VP1 is
not visible in lane 4 (plants inoculated with TMV-VP1) but
a faint band in the expected size range (ca. 24 kDa) is the
primary band visible in the TMV-VPl-HISc-derived sample
processed with the IMAC beads (lane 6, Fig. 2A). This band
was shown to have the expected His-tag by Western blot analysis using the anti-6xHis mAb (Fig. 2B). This IMAC sample,
as well as the crude protein extract from the VP1 inoculated
leaves, was confirmed to contain approximately equivalent
amounts of the VP1 recombinant protein by using polyclonal
VP1-antiserum in the Western blot (Fig. 2C). These results
clearly show that the one-step IMAC procedure was very effective at purifying the recombinant His-tagged VP1 while
still maintaining its antigenic properties. The estimated yield
using known protein standards was approximately 6–8 g of
VPl-His per gram of fresh plant tissue.
3.2. Expression of HIV-1 p24 using the TMV30B-HISc
vector
Leaves were inoculated with the TMV-p24HISc vector as
described in the previous section. Production of recombinant
p24-His was directly analyzed by SDS-PAGE from the IMAC
resin after incubation with a plant sap sample equivalent to
25 mg of fresh leaf inoculated tissue. The stained gel shows
a predominant band of approximately 24 kDa and a second
band with lower intensity around 50 kDa, which is likely a
dimer (Fig. 3A). Visual analysis revealed that the amount
of recombinant protein isolated from an equivalent amount
of plant tissue was considerably higher for p24-His than for
VPl-His. Western blot assays confirmed the expected antigenic nature of the two bands isolated from the TMV-p24HISc inoculated leaves. Both the anti-6xHis mAb (Fig. 3B)
and HIV-1 specific human antiserum (Fig. 3C) detected the
same monomer (ca. 25 kDa) and suspected dimer (ca. 50 kDa)
bands, confirming the presence of both His and p24 specific
antigenic sequences in the proteins.

Fig. 2. Expression of VP1 using the TMV-30B-HISc vector. All protein samples were derived from approximately 25 mg of fresh leaves. Lanes 1 and 5,
two different molecular weight markers (MWM). Panel A: Coomassie blue stained gel of total proteins obtained from a mock infected leaf (lane 2) or leaves
inoculated with TMV-30B (lane 3), TMV-VP1 (lane 4) and TMV-VPlHis after MAC binding (lane 6). Proteins in lane 6 derived directly from a sample of the
IMAC beads after incubation with the plant sap and washing. Panel B: Western blot from the same gel probed with an anti-6xHis mAb. Panel C: same blot
re-probed with a polyclonal mouse antiserum against VP1.
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Fig. 3. Expression of p24-His using the TMV-30B-HISc vector. Panels A–C: Lane 1, His-tagged MW markers; Lane 2, proteins bound to MAC beads after
adsorption from plant sap extracted from 25 mg of fresh leaf tissue. Panel A: Coomassie blue stained gel. The arrow indicates the position of a dimeric form of
the p24-His. Panel B: Western blot from the same gel probed with an anti-6xHis mAb. Panel C: Lane 2, MAC sample probed with HIV-1 positive human sera;
in lane 1, His-tagged MW marker lane was excised from the blot and probed with the anti-6xHis mAb.

3.3. Studies on the antigenic properties of the p24-His
We next tested the utility of the TMV-p24 HISc vector for
production of useful quantities of p24-His reagent for both
HIV-1 detection and immunogen utilization. It was first essential to determine if the protein maintained its antigenic
properties after its expression and purification from plants.
To determine this, we inoculated rabbits with recombinant
protein purified from plants and assessed if the humoral immune response to recombinant p24-His after immunization
could recognize the native p24 from HIV-1.
Production of the p24-His was scaled up by inoculating
10 N. benthamiana plants using ∼5 g of RNA transcript
derived from the TMV-p24-HISc vector per plant. Approximately, 25 g of inoculated tissue was processed and the IMAC
bound protein was eluted from a column as described in
Section 2. A total of 2.5 mg of purified p24-His was eluted
from the MAC column at a concentration of 0.5 mg of p24His/ml of elution buffer, thus providing an approximated
yield of 100 g of purified p24-His per gram of fresh inoculated tissue.
Animals received two immunizations with an immunogen
formulated with the protein obtained from the IMAC columns
without further purification. Both rabbits developed a specific humoral response against the p24-His after the second
immunization, as detected by Western blot analysis against
the homologous protein (data not shown) and by IFA analysis
(Brayfield et al., 2003). A representative IFA experiment
from the first bleed of the immunized rabbits is presented in
Fig. 4. This result shows very clearly that the immune sera
recognized the native HIV-1 capsid protein expressed in the
infected cells, even though the HUT78/ARV cells used for
the IFA were infected with an infectious clone of a clade B
HIV-1 isolate. These observations suggested that: (i) despite
the denaturing conditions used for elution of the protein
from IMAC columns, many of the antigenic properties of the
HIV-1 capsid protein were preserved in the purified p24-His

Fig. 4. Immunofluorescence assay using HUT 78/ARV cells. Panel A: Preimmune serum. Panel B: Serum from p24-His immunized rabbit at 30 days
post-immunization.

and (ii) that the antibodies raised against clade C p24 protein
can also react with native clade B p24 protein.
Finally, a subset of patients from an ongoing study of
mother to child transmission of HIV-1 from Zambia were
used to determine if p24-His antigen could be used in Western blot assays to confirm HIV-1 test results. In this study,
commercial rapid tests (DetermineTM and CapillusTM ) were
used for HIV-1 serological testing at the time of delivery.
A subset of patients with concordant positive (n = 70) and
concordant negative (n = 47) results between the two assays,
were used in Western blots. All 70 rapid test positive samples
were also Western blot positive, while all those negative by
the rapid tests were also negative in Western blots (Table 1).
Table 1
Use of recombinant p24-His for Western blot confirmation of HIV-1
serostatus
HIV-1 serostatusa

Rapid tests (+)

p24-His WB (+)

Positive
Negative

70
47

70
0

a Concordant positive test results with the CapilusTM and DetermineTM
assays; performed according to the manufacturer.
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4. Discussion
Previous experience using the TMV-30B vector demonstrated that not all foreign inserts were equally stable and that
the transcription of the foreign genes cloned into the vector
was variable and generally decreased with increasing size of
the foreign gene insert. We also encountered problems with
reliable and specific immuno-detection of several animal viral proteins in the plant extracts, due to background problems
resulting from cross-reactivity of the animal viral antiserum
with plant proteins.
The facile production of recombinant HIV-1 structural
proteins in plants is described for potential use in diagnostics as well as in vaccine production. We cloned the FMDV
VP1 structural protein into the new vector TMV-30B-HISc
as a model to compare it with the previously reported TMVVP1 construction (Wigdorovitz et al., 1999). The simple addition of a His-tag to the recombinant protein expressed in
the well-documented TMV-30B vector provides a very useful and simple means for producing recombinant proteins in
high concentrations that can be purified easily and used as
diagnostic antigens or immunogens.
Both recombinant VPl-His and p24-His proteins strongly
reacted against specific antisera and also against a commercially available anti-6xHis mAb, indicating that this expression system may be a practical alternative for detecting proteins for which no specific antiserum is available. Protein
purification based on the IMAC technology allowed us to
achieve high product yield in one step using a relatively simple methodology. The inclusion of urea in both the extraction
and elution buffers, substantially improved solubilization of
proteins from total leaf extracts which may have also improved the binding specificity. The addition of urea did not
noticeably affect the antigenicity of the recombinant products. This is consistent with previous reports showing that
urea concentrations as high as 10 M, while increasing protein
solubility, did not negatively effect the binding and haemagglutination activities of bovine rotavirus VP8∗ (Lee et al.,
1995) or reovirus l proteins (Yeung et al., 1987).
Application for expression of the membrane targeted HIV
glycoproteins gp41 and gp120 proved less tractable. Although both recombinant products were successfully produced and detected in Western blot assays, purification yields
were lower than expected since these HIV-1 glycoproteins
naturally tend to remain associated to membrane structures,
preventing efficient solubilization from crude plant extracts
(data not shown).
Immunological analysis of the p24-His confirmed that
most of the native antigenic properties were preserved in the
plant-produced protein. The p24 ORF used in this study was
amplified from a genomic DNA from a patient infected with
HIV-1 clade C from Zambia. Our Western blot assays, using
the p24-His as antigen, unambiguously confirmed 100% of
the serum samples from clade C HIV-1 infected patients in a
set of Zambia mothers and infants. Furthermore, in a previous
report, all 44 HIV-1 mothers and infants who seroconverted

during the first year after delivery, as determined by two rapid
tests and IFA, were also Western blot positive using p24-His.
(Brayfield et al., 2003). Importantly, antibodies induced by
the p24-His were also reactive against a native p24 from a
different clade (clade B), as shown in the IFA experiments.
These results suggest that the recombinant p24-His protein
has the potential for use in diagnostic testing for infection
with multiple clades of HIV-1. Further testing of sera from
patients infected with other HIV-1 clades and from patients
comprising other HIV-1 risk groups will need to be examined
to substantiate this finding.
Yields obtained for VPl-His were similar to those obtained
for VP1 using the TMV-VP1 vector, reaching concentrations
around 6–8 g/g of fresh leaves. However, under the same
experimental conditions, the amount of recombinant p24-His
was 10–15 times higher than for VPl-His. It seems unlikely
that the very high levels of recombinant p24-His observed
were the result of higher accumulation of p24-His transcript
as judged from previous studies which showed that transcription levels of foreign inserts in theTMV-30B vector were
consistently similar for inserts of about the same size (unpublished results). These results most likely reflect the inherent
stability of this protein as reported in other systems. The plant
derived p24-His preparations consistently had a second band
that we interpret to be a dimer of the p24-His protein. This
observation had been reported previously for production of
p24 in E. coli (Ehrlich et al., 1990, 1992), insect cells (Gay
et al., 1998) and during in vitro assembly experiments of purified p24 (Gross et al., 1997). These studies showed that the
capsid protein of HIV-1, when overexpressed, naturally tends
to produce stable dimeric and oligomeric forms. We suspect,
but did not confirm, that p24-His forms higher order structures in the plant tissue that makes the protein more resistant
to endogenous proteases (Gross et al., 1998).
In conclusion, our results demonstrate that both the FMDV
VP1 and the HIV-1 capsid antigen could be reliably produced in plants using the TMV-30B-HISc vector. Both proteins could be easily monitored in crude plant extracts using
anti-His antibody and readily purified using the affinity resin.
Importantly, we also show here that recombinant p24-His,
purified with high yields from crude plant extracts, retained
its antigenic and immunogenic properties after purification
making it suitable for use as a specific diagnostic reagent and
potential inclusion as a vaccine antigen. We estimate that the
reagent we purified from ∼25 g of infected plant tissue could
be used to conduct over 20,000 HIV tests indicating that this
technology can potentially be of great use for production of
specific diagnostic reagents in resource limited areas of the
world.
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